Peptide library / Melanotan I

Melanotan I

Melanotan I is the development name commonly associated with afamelanotide, a synthetic alpha-MSH analog. Scenesse is a specific prescription implant formulation.

Peptide & blend guide

The short version

Why people discuss it
Discussed for tanning and pigmentation; research-vial use is distinct from the afamelanotide implant. Community interest does not establish benefit or a suitable treatment.
What it is
Melanotan I is the development name commonly associated with afamelanotide, a synthetic alpha-MSH analog. Scenesse is a specific prescription implant formulation.
Biggest caution
Scenesse evidence applies to a specialist-administered implant for a narrow phototoxicity indication. It does not validate tanning injections, nasal products or unspecified Melanotan I preparations.
Stack context
Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Legacy community reference: no complete dosing regimen was independently corroborated by the two new source collections.

Subcutaneous injection

Community reference · Not clinical guidance
Amount
0.25–0.5 mg
Frequency
Once daily during loading
Duration / phase
10–14 days; maintenance 1–2 times weekly

Community pattern; not equivalent to the Scenesse implant The new inbox sources do not independently corroborate this complete regimen. Reference only; this does not establish safety, effectiveness or individual suitability.

Reference source · reviewed 2026-09-12
Evidence & sources · Community source profile

AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.

Back to the peptide library